India: Jubilant Life Sciences to buy US-based Triad Isotopes’ Radiopharmacy unit

Visual from the company website

Jubilant Life Sciences Ltd. has signed an agreement to buy the radiopharmacy business of U.S. based Triad Isotopes Inc. The drug maker will carry out the agreement through its wholly-owned subsidiary, Jubilant Pharma Ltd.

The transaction, which will be funded through Jubilant Pharma’s internal accruals, is also likely to be earnings accretive in the first full year of operations, the company said in its exchange filing.

It also said that the closing of the transaction is subject to customary conditions including regulatory approvals. The acquisition is likely to provide Jubilant an access to hospital networks with an ability to deliver more than 3 million patient doses annually.

Triad had recorded revenues in excess of $225 million during 2016 and has the second largest radiopharmacy network in the U.S. with more than 50 pharmacies.

Shares of Jubilant Life Sciences gained as much as 1.7 percent to Rs 747 in early trade on the Bombay Stock Exchange. So far this year, the stock (+18.3 percent) has managed to outperform both the Nifty Pharma (+0.2 percent) and the Nifty 50 Index (+13.9 percent).

Also Read

India: Jubilant Life Sciences exploring Singapore IPO for pharma unit
Jubilant Life Sciences raises $15m

Bloomberg

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.